Literature DB >> 8823314

Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera.

M A Robin1, M Maratrat, M Le Roy, F P Le Breton, E Bonierbale, P Dansette, F Ballet, D Mansuy, D Pessayre.   

Abstract

Patients with tienilic acid hepatitis exhibit autoantibodies that recognize unalkylated cytochrome P450 2C9 in humans but recognize 2C11 in rats. Our aim was to determine whether the immune reaction is also directed against neoantigens. Rats were treated with tienilic acid and hepatocytes were isolated. Immunoprecipitation, immunoblotting, and flow cytometry experiments were performed with an anti-tienilic acid or an anti-cytochrome P450 2C11 antibody. Cytochrome P450 2C11 was the main microsomal or plasma membrane protein that was alkylated by tienilic acid. Inhibitors of vesicular transport decreased flow cytometric recognition of both unalkylated and tienilic acid-alkylated cytochrome P450 2C11 on the plasma membrane of cultured hepatocytes. Tienilic acid hepatitis sera that were preadsorbed on microsomes from untreated rats (to remove autoantibodies), poorly recognized untreated hepatocytes in flow cytometry experiments, but better recognized tienilic acid-treated hepatocytes. This recognition was decreased by adsorption with tienilic acid or by preexposure to the anti-tienilic acid or the anti-cytochrome P450 2C11 antibody. We conclude that cytochrome P450 2C11 is alkylated by tienilic acid and follows a vesicular route to the plasma membrane. Tienilic acid hepatitis sera contain antibodies against this tienilic acid adduct, in addition to the previously described anticytochrome P450 autoantibodies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823314      PMCID: PMC507575          DOI: 10.1172/JCI118936

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  Immune mechanisms in tienilic acid associated hepatotoxicity.

Authors:  J Neuberger; R Williams
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

2.  A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis.

Authors:  J C Homberg; C Andre; N Abuaf
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

3.  Immunological studies on the mechanism of halothane-induced hepatotoxicity: immunohistochemical evidence of trifluoroacetylated hepatocytes.

Authors:  H Satoh; Y Fukuda; D K Anderson; V J Ferrans; J R Gillette; L R Pohl
Journal:  J Pharmacol Exp Ther       Date:  1985-06       Impact factor: 4.030

4.  Presence of covalently bound metabolites on rat hepatocyte plasma membrane proteins after administration of isaxonine, a drug leading to immunoallergic hepatitis in man.

Authors:  J Loeper; V Descatoire; G Amouyal; P Lettéron; D Larrey; D Pessayre
Journal:  Hepatology       Date:  1989-05       Impact factor: 17.425

5.  Ticrynafen-associated hepatic injury: analysis of 340 cases.

Authors:  H J Zimmerman; J H Lewis; K G Ishak; W C Maddrey
Journal:  Hepatology       Date:  1984 Mar-Apr       Impact factor: 17.425

6.  Decrease in hepatic cytochrome P-450 by cobalt. Evidence for a role of cobalt protoporphyrin.

Authors:  J F Sinclair; P R Sinclair; J F Healey; E L Smith; H L Bonkowsky
Journal:  Biochem J       Date:  1982-04-15       Impact factor: 3.857

7.  Antibody mediated hepatocyte injury in methyl dopa induced hepatotoxicity.

Authors:  J Neuberger; J G Kenna; K Nouri Aria; R Williams
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

8.  Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug.

Authors:  P Beaune; P M Dansette; D Mansuy; L Kiffel; M Finck; C Amar; J P Leroux; J C Homberg
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

9.  Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid.

Authors:  M P López-Garcia; P M Dansette; D Mansuy
Journal:  Biochemistry       Date:  1994-01-11       Impact factor: 3.162

10.  Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane.

Authors:  J G Kenna; H Satoh; D D Christ; L R Pohl
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

View more
  9 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.

Authors:  Michael Mohutsky; Stephen D Hall
Journal:  Methods Mol Biol       Date:  2021

3.  Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.

Authors:  L Muratori; M Parola; A Ripalti; G Robino; P Muratori; G Bellomo; R Carini; M Lenzi; M P Landini; E Albano; F B Bianchi
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

Review 4.  Drug-induced immunotoxicity.

Authors:  P M Dansette; E Bonierbale; C Minoletti; P H Beaune; D Pessayre; D Mansuy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.441

5.  Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.

Authors:  Imir G Metushi; Corron Sanders; William M Lee; Jack Uetrecht
Journal:  Hepatology       Date:  2014-01-27       Impact factor: 17.425

Review 6.  The functional effects of physical interactions involving cytochromes P450: putative mechanisms of action and the extent of these effects in biological membranes.

Authors:  James R Reed; Wayne L Backes
Journal:  Drug Metab Rev       Date:  2016-08       Impact factor: 4.518

Review 7.  Idiosyncratic adverse drug reactions: current concepts.

Authors:  Jack Uetrecht; Dean J Naisbitt
Journal:  Pharmacol Rev       Date:  2013-03-08       Impact factor: 25.468

8.  Modeling the Bioactivation and Subsequent Reactivity of Drugs.

Authors:  Tyler B Hughes; Noah Flynn; Na Le Dang; S Joshua Swamidass
Journal:  Chem Res Toxicol       Date:  2021-01-26       Impact factor: 3.739

9.  XenoNet: Inference and Likelihood of Intermediate Metabolite Formation.

Authors:  Noah R Flynn; Na Le Dang; Michael D Ward; S Joshua Swamidass
Journal:  J Chem Inf Model       Date:  2020-06-29       Impact factor: 4.956

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.